Latest Stock Market News

Alembic Pharma has reported a Q1 net profit of INR 121 crore, up from a net loss of INR 66 crore YoY, led by increased sales growth across its segments. The Indian branded business recorded a 9% YoY growth to INR 524 crore, while US generics saw 6% YoY growth to INR 354 crore.

The contract research and manufacturing serivces (CDMO) revenues rose 17% YoY to Rs 898 crore led by order inflow momentum and strong execution in Q1FY24.

"Large parts of what we would see around us is going to go green. For example, ten years back, solar power was seen as something that we need to do because we need to go clean. But today, that is the cheapest form of power so that is the only way to go. So perforce, we are going to have larger and greener projects and we will have larger amounts of funding going for these projects."

Consolidated revenue from operations increased 10.5% YoY to Rs 1,929 crore. Express parcel shipment volumes grew 19% YoY to 182 million in the quarter. Volumes grew by over 2 million shipments from the March quarter eventhough the June quarter is traditionally a seasonally weak period for the sector

The hourly momentum indicator has also reached the equilibrium line indicating that the pullback has matured and can begin a new cycle on the downside, said Nagaraj Shetti of HDFC Securities.

On the technical charts, the RSI of the stock stood at 44.53.

The company, which also operates in the United States and Saudi Arabia, said its revenue from operations more than tripled to 40.69 billion rupees. The total expenses came in at 38.79 billion rupees, as input costs nearly doubled.

"If someone is only talking about returns and especially high returns, then that is the first red flag for me because if I am not sure about the product especially if it is investments, people should be talking about what my ambition is from my money, what my aspirations are for my family and how can my money take me there."

"Coming to Adani Enterprises, instead of retail investors, this kind of business is definitely more meaningful if you are an institutional investor like pension fund, insurance fund, sovereign fund or a large-sized hedge fund, because it is producing unlocking of value in coming years. Also, I see the entire infrastructure portfolio of the company at the group level to begin with and then respective companies thereafter."

Insecticides (India), a leading agrochemicals company, showcased impressive market performance by crossing its 100-day SMA at Rs 457.99, with a closing price of Rs 464.55 on August 3.